These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36958327)

  • 1. Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study.
    Niehues JM; Quirke P; West NP; Grabsch HI; van Treeck M; Schirris Y; Veldhuizen GP; Hutchins GGA; Richman SD; Foersch S; Brinker TJ; Fukuoka J; Bychkov A; Uegami W; Truhn D; Brenner H; Brobeil A; Hoffmeister M; Kather JN
    Cell Rep Med; 2023 Apr; 4(4):100980. PubMed ID: 36958327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania.
    Brinzan CS; Aschie M; Cozaru GC; Deacu M; Dumitru E; Burlacu I; Mitroi A
    Medicine (Baltimore); 2022 Oct; 101(40):e30979. PubMed ID: 36221415
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Jin J; Shi Y; Zhang S; Yang S
    Acta Oncol; 2020 Jan; 59(1):66-74. PubMed ID: 31545109
    [No Abstract]   [Full Text] [Related]  

  • 5. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and epigenetic characteristics of patients with colorectal cancer from Uruguay.
    Vital M; Carusso F; Vergara C; Neffa F; Della Valle A; Esperón P
    Pathol Res Pract; 2023 Jan; 241():154264. PubMed ID: 36495761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
    Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
    J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.
    Susanti S; Fadhil W; Murtaza S; Hassall JC; Ebili HO; Oniscu A; Ilyas M
    J Clin Pathol; 2019 Mar; 72(3):263-264. PubMed ID: 30361395
    [No Abstract]   [Full Text] [Related]  

  • 10. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
    Yanus GA; Belyaeva AV; Ivantsov AO; Kuligina ESh; Suspitsin EN; Mitiushkina NV; Aleksakhina SN; Iyevleva AG; Zaitseva OA; Yatsuk OS; Gorodnova TV; Strelkova TN; Efremova SA; Lepenchuk AY; Ochir-Garyaev AN; Paneyah MB; Matsko DE; Togo AV; Imyanitov EN
    Med Oncol; 2013; 30(3):686. PubMed ID: 23943423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
    Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
    J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
    Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
    APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer].
    Danishevich AM; Pospehova NI; Stroganova AM; Golovina DA; Nikulin MP; Kalinin AE; Nikolaev SE; Stilidi IS; Lyubchenko LN
    Mol Biol (Mosk); 2023; 57(1):71-84. PubMed ID: 36976740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.